ArticleMaedica2026
The Role of α-2 Adrenergic Receptor Agonist Dexmedetomidine Alone or in Combination with Ropivacaine in Postoperative Pain Management Following Breast Surgery.
Article in Maedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Postoperative pain following breast surgery remains a significant clinical challenge and may delay recovery while increasing the need for systemic analgesics. Dexmedetomidine, a selective α-2 adrenergic receptor agonist, has been shown to enhance the analgesic effects of local anesthetics. This randomized comparative study aimed to evaluate the analgesic efficacy of dexmedetomidine administered alone or in combination with ropivacaine in patients undergoing modified radical mastectomy. Materials and methods: This prospective randomized trial was conducted in Hippokrateio Hospital of Athens, Greece, between October 2021 and September 2022, in the first Propaedeutic Surgical Clinic, National and Kapodistrian University of Athens. Ninety female patients (Angle Side Angle - ASA I-II) aged 25-65 years old, who had been scheduled for modified radical mastectomy, were randomized into three groups (n = 30 each). Group R received 0.375% ropivacaine, Group D, dexmedetomidine (1 μg/kg) and Group RD, a combination of both agents. A standardized volume of 10 mL was infiltrated using a landmark-guided technique along the anatomical course of the long thoracic nerve and the adjacent peri-incisional fascial plane before wound closure. Postoperative pain was evaluated using the visual analog scale (VAS) at 0, 4, 8, 16, and 24 hours and only at rest measured in our study. Rescue analgesia with intravenous paracetamol and tramadol was recorded. Statistical analysis included one-way and repeated-measures ANOVA, with significance set at p < 0.05. Results: The RD group demonstrated clinically meaningful threshold VAS scores at all-time points (p < 0.001) and required substantially less rescue analgesia than Groups R and D, confirming the additive analgesic effect of dexmedetomidine when combined with ropivacaine. Conclusions: The combination of dexmedetomidine and ropivacaine significantly improves postoperative analgesia following modified radical mastectomy without increasing adverse effects. Dexmedetomidine appears to be a safe and effective adjuvant within multimodal analgesia strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.